Mandate

Vinge advises ITAB in connection with a recapitalisation of SEK 868 million

February 11, 2021 Capital Markets and Public M&A

The recapitalisation is carried out to strengthen ITAB’s capital structure to reduce the financial leverage of the group, to invest in the One ITAB transformation plan and to provide sufficient headroom to the business given the Covid-19 situation.

The recapitalisation entails that the equity is strengthened by approx. SEK 868 million by a rights issue of SEK 768 million and a set-off issue of SEK 100 million and entails further that Aeternum Capital becomes ITAB’s largest shareholder with a holding of approx. 25 percent of the shares. First day of trading in the new class B shares issued as a result of the recapitalisation is estimated to be 22 March 2021.

ITAB sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The offer includes custom-made fitting concepts, innovative solutions for the checkout area, professional lighting systems and interactive products. Customers include major retail chains throughout most of Europe. ITAB’s class B shares are listed on Nasdaq Stockholm.

Vinge’s team mainly consisted of Charlotte Levin, Rikard Lindahl, Annika Nyberg Ekenberg, Clara Sohlberg, Mikaela Falkner, Henrik Wastenson and David Bokliden.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024